Core Viewpoint - The article provides an overview of recent IPO activities across Hong Kong, the US, and A-shares, highlighting several companies preparing for their public listings and their respective market positions. Group 1: Muxi Integrated Circuit - Muxi Integrated Circuit (Shanghai) Co., Ltd. officially listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 17, 2025, with the stock code "688802" [3] - Founded in 2020, Muxi is a leading domestic high-performance general-purpose GPU product company, focusing on the research, design, and sales of GPUs for AI training, inference, general computing, and graphics rendering [3] - Muxi's GPU products have achieved cumulative sales of over 25,000 units by the end of March 2025, with a revenue compound growth rate of 4074.52% over the past three years, and revenue of 915 million yuan in the first half of this year [5] Group 2: Woan Robotics - Woan Robotics (Shenzhen) Co., Ltd. plans to officially list on the Hong Kong Stock Exchange on December 30, 2025, with the stock code "6600" [7] - The company aims to become the "first stock of AI-embodied household robots," with an IPO market valuation between 14 billion and 18 billion HKD, raising up to 1.8 billion HKD [8] - Woan Robotics is recognized as the only company globally to comprehensively layout AI-embodied household robot systems, holding an 11.9% market share in the sector by 2024 [10] Group 3: Xunce Technology - Xunce Technology plans to list on the Hong Kong Stock Exchange on December 30, 2025, with the stock code "3317," marking it as the first company in China's AI data sector to complete an IPO [12] - The company aims to raise up to 1.2375 billion HKD through its IPO, with a focus on real-time data infrastructure and analysis solutions [12] - Xunce Technology's real-time data solutions are noted for their speed and consistency, optimizing business efficiency and flexibility [14] Group 4: InSilico Medicine - InSilico Medicine plans to list on the Hong Kong Stock Exchange on December 30, 2025, with the stock code "3696," aiming to raise up to 2.3 billion HKD [16] - The company is recognized as the largest biotech IPO in Hong Kong this year, with a focus on AI-driven drug development across various industries [17] - InSilico's core asset, Rentosertib, is a first-in-class candidate drug for idiopathic pulmonary fibrosis, showcasing the company's innovative capabilities [18] Group 5: Linqingxuan - Linqingxuan Cosmetics Group plans to list on the Hong Kong Stock Exchange on December 30, 2025, with the stock code "2657," aiming to raise over 1 billion HKD [21] - The company is positioned as the leading high-end domestic skincare brand in China, with a complete product matrix in anti-wrinkle and firming skincare [22] - Linqingxuan ranks first among all domestic high-end skincare brands in China by retail revenue in 2024 [22] Group 6: 51WORLD - 51WORLD plans to list on the Hong Kong Stock Exchange on December 30, 2025, with the stock code "6651," aiming to become the "first stock of Physical AI" [24] - The company has established a comprehensive technology capability in Physical AI, with products applied in various industries globally [24] - 51WORLD's revenue has shown significant growth, with a 63.6% increase in the first half of this year compared to the same period last year [26] Group 7: Qingsong Health Group - Qingsong Health Group plans to list on the Hong Kong Stock Exchange on December 23, 2025, with the stock code "2661," aiming to raise over 600 million HKD [28] - The company operates as a one-stop digital health and insurance service platform, covering various health-related services [28] - Qingsong Health Group's revenue has grown significantly, with an 84.7% increase in the first half of this year compared to the previous year [29] Group 8: Biran Technology - Biran Technology has passed the hearing for its listing on the Hong Kong Stock Exchange, focusing on general intelligent computing solutions [31] - The company has shown strong growth potential, with significant sales agreements in place and a focus on AI data centers and telecommunications [32] Group 9: Zhipu Technology - Zhipu Technology has passed the hearing for its listing on the Hong Kong Stock Exchange, aiming to become the "first stock of global large models" [35] - The company has achieved significant revenue growth, with a compound annual growth rate of 130% from 2022 to 2024 [36] Group 10: Tiandu Intelligent Chip - Tiandu Intelligent Chip has passed the hearing for its listing on the Hong Kong Stock Exchange, focusing on general-purpose GPU chips [38] - The company has seen a significant increase in customer numbers and product shipments, reflecting strong market recognition [39]

| : [編纂]股H股(視乎[編纂]及 | [编纂]的[编纂]數目 | 超額配股權行使與否而定 | | | --- | --- | --- | --- | | [編纂]數目 | [編纂]股H股(視乎[編纂]行使 | : | 與否而定及可予重新分配) | | [编纂]數目 | [編纂]股H股(視乎[編纂]行使與否而定、可予重新分配 | : | 及視乎[编纂]行使與否而定) | | : | 每股H股[編纂]港元,另加1.0%經紀佣金、 | 最高 编纂] | 0.0027%證監會交易徵費、 | | 0.00565%香港聯交所交易費及 | 0.00015%會財局交易徵費 | | | | (須於[編纂]時以港元繳足,多繳股款可予退還) | 每股H股人民幣1.00元 | 面值 | : | | 编纂] | ■【 | | | | 獨家保薦人 | | | | | 1 | | | | 据港交所12月17日披露，深圳迅策科技股份有限公司(简称：迅策科技)通过港交所主板上市聆讯，国泰君安国际为独家保荐人。 招股书显示，迅策科技是中国实时数据基础设施及分析解决方案供应商。公司为全行业企业提供涵盖数据基础设施及数据分析的实时信息技术解 ...

智通财经APP讯，迅策(03317)于2025年12月18日至12月23日招股，该公司拟全球发售2250万股，其中香 港发售占10%，国际发售占90%，另有15%超额配股权，每股发售价48-55港元。每手100股，预期股份 将于2025年12月30日在联交所开始买卖。 公司是中国实时数据基础设施及分析解决方案供应商。公司为全行业企业提供涵盖数据基础设施及数据 分析的实时信息技术解决方案。公司的系统整合服务促进客户拥有的环境(包括自主管理云端及本地部 署系统)中的无缝部署。 数据基础设施根据处理机制及效率分为实时及非实时两类。2024年，中国实时数据基础设施及分析市场 价值为人民币187亿元，占中国数据基础设施及分析市场总量4.5%。按收入计算，公司在此分部中排名 第四，市场份额为3.4%。实时及非实时的分类满足不同的资料处理需求且不可互换。 公司产品组合的核心是实时数据基础设施，一个统一数据平台，可以在数毫秒至数秒内收集、清理、管 理、分析及治理来自多个来源的异构数据。这意味着数据一经收集后，几乎可以立即处理并可用于决 策、分析或进一步行动。建立在该基础上的是公司的数据分析应用层面，利用相关基础设施来产生洞 ...

Core Viewpoint - Shenzhen Xunce Technology Co., Ltd. is seeking to go public on the Hong Kong Stock Exchange after two previous failed attempts, highlighting its ongoing efforts to secure funding despite facing intense competition in the real-time data infrastructure and analytics market [1][30]. Company Overview - Founded in 2016, Xunce Technology specializes in real-time data infrastructure and analytics solutions, with a focus on high R&D investment and a current lack of profitability [1][9]. - The company has received significant investments from major firms including Tencent, Alibaba, and Goldman Sachs, with a post-money valuation of 6.22 billion yuan as of November 2023 [2][3][4]. Financial Performance - Xunce Technology reported cumulative losses of 366 million yuan over three and a half years, with R&D expenses exceeding 70% of revenue [11][14]. - Revenue figures for the years 2022, 2023, and 2024 were 288.99 million yuan, 530.46 million yuan, and 631.98 million yuan respectively, with a decline in revenue noted in the first half of 2025 [14][15]. - The company’s gross profit margins fluctuated between 66.7% and 79% during the reporting periods, with a notable decrease in 2025 due to increased demand for customized solutions from asset management clients [16][17]. Market Position - Xunce Technology holds approximately 3.4% market share in China's real-time data infrastructure and analytics market, ranking fourth by revenue in 2024 [22][28]. - The company is particularly strong in the asset management sector, where it commands an 11.6% market share, making it the leading player in that niche [28][30]. - The overall market for real-time data infrastructure and analytics in China is projected to grow significantly, reaching 18.7 billion yuan in 2024, with a compound annual growth rate of 46.1% from 2020 to 2024 [25][28]. Client Base and Revenue Model - As of 2024, Xunce Technology had 232 paying clients, with 177 from the asset management sector and 55 from other industries, indicating a diversification in its client base [12][14]. - The average revenue per user (ARPU) for asset management clients was 1.38 million yuan, while for clients in other sectors, it was significantly higher at 7.05 million yuan [12][14]. R&D and Human Resources - The company employs around 320 R&D personnel, accounting for approximately 67% of its total workforce, reflecting its commitment to innovation [18]. - R&D expenditures have consistently represented a large portion of revenue, with figures of 2.59 billion yuan, 3.79 billion yuan, and 4.5 billion yuan reported over the last three years [18].

Core Insights - Shenzhen Xunce Technology is facing significant financial challenges as it approaches its IPO, with a drastic decline in revenue growth and an increase in net loss rate from 12.0% in 2023 to 54.6% in the first half of 2025 [1] Group 1: Business Focus - The company specializes in real-time data infrastructure and analysis solutions, primarily serving asset managers, and ranks fourth in the Chinese market for real-time data infrastructure and analysis, holding an 11.6% market share [2] - The solutions are modular, consisting of over 300 modules forming seven major solutions, with a customized pricing model based on data volume and processing speed [3] Group 2: Financial Performance - Revenue growth has fluctuated significantly, with a peak of 84.3% in 2023, followed by a decline to -30.0% in the first half of 2025, attributed to intensified market competition and project delays [4] - The net loss has widened, with the net loss rate increasing from 12.0% in 2023 to 54.6% in the first half of 2025, primarily due to increased R&D, administrative, and sales expenses amid declining revenue [5][8] - Gross margin has shown a downward trend, dropping to 66.7% in the first half of 2025, likely due to rising costs associated with customized solutions and new market expansions [6] Group 3: Revenue Composition - The revenue composition indicates a decline in the asset management sector's share, from 74.4% in 2022 to 47.3% in the first half of 2025, while the share from diversified industries has increased, reflecting the company's strategic expansion efforts [9] Group 4: Risks and Challenges - The company faces potential risks from related party transactions, which are not disclosed in the prospectus but could arise in the future [10] - Continuous losses present financial challenges, necessitating substantial funding for R&D and market expansion, with potential impacts on cash flow if profitability does not improve [11] - Intense competition in the asset management sector requires the company to maintain innovation and enhance competitiveness [12] - High customer concentration poses a risk, as revenue from the top five clients accounted for significant portions of total revenue, indicating vulnerability to client loss [13] Group 5: Governance and Management - The ownership structure is relatively concentrated, with a major shareholder controlling approximately 28.86% of the issued share capital, which may enhance decision-making efficiency but also raises concerns about minority shareholder interests [15] - The lack of detailed disclosures regarding the compensation and incentive mechanisms for core management may impact talent retention and company growth [16]